Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial
Authors:
Open Access
- 19 July 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (7) , e0200539
Abstract
The emergence of multidrug resistant-tuberculosis (MDR-TB), defined as Mycobacterium tuberculosis strains with in vitro resistance to at least isoniazid and rifampicin, has necessitated evaluation and validation of appropriate surrogate endpoints for treatment response in drug trials for MDR-TB. The trial that has demonstrated efficacy of bedaquiline, a diarylquinoline that inhibits mycobacterial ATP synthase, possesses the requisite features to conduct this evaluation. Approval of bedaquiline for use in MDR-TB was based primarily on the results of the controlled C208 Stage II study (ClinicalTrials.gov number, NCT00449644) including 160 patients randomized 1:1 to receive bedaquiline or placebo for 24 weeks when added to an 18–24-month preferred five-drug background regimen. Since randomization in C208 Stage II was preserved until study end, the trial results allow for the investigation of the complex relationship between sustained durable outcome with either Week 8 or Week 24 culture conversion as putative surrogate endpoints. The relationship between Week 120 outcome with Week 8 or Week 24 culture conversion was investigated using a descriptive analysis and with a recently developed statistical methodology for surrogate endpoint evaluation using methods of causal inference. The results demonstrate that sputum culture conversion at 24 weeks is more reliable than sputum culture conversion at 8 weeks when assessing the outcome of adding one new drug to a MDR-TB regimen.Keywords
Funding Information
- Janssen
This publication has 28 references indexed in Scilit:
- Month 2 Culture Status and Treatment Duration as Predictors of Tuberculosis Relapse Risk in a Meta-Regression ModelPLOS ONE, 2013
- An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and RelapsePLOS ONE, 2013
- Linezolid for Treatment of Chronic Extensively Drug-Resistant TuberculosisNew England Journal of Medicine, 2012
- Delamanid for Multidrug-Resistant Pulmonary TuberculosisNew England Journal of Medicine, 2012
- Early clinical development of anti-tuberculosis drugs: Science, statistics and sterilizing activityTuberculosis, 2010
- The Diarylquinoline TMC207 for Multidrug-Resistant TuberculosisNew England Journal of Medicine, 2009
- Surrogate Endpoints And FDA’s Accelerated Approval ProcessHealth Affairs, 2005
- A solution to the problem of separation in logistic regressionStatistics in Medicine, 2002
- The validation of surrogate endpoints in meta-analyses of randomized experimentsBiostatistics, 2000
- Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: The results up to 30 monthsTubercle, 1981